Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted alpha-therapy: past, present, future?

Martin W Brechbiel1

  • 1Radioimmune & Inorganic Chemistry Section Radiation Oncology Branch, NCI, NIH Building 10, Room 1B40 10 Center Drive Bethesda, MD 20892-1088, USA. martinwb@mail.nih.gov

Dalton Transactions (Cambridge, England : 2003)
|November 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On the Importance of Extracting the Needle from the Haystack.

Cancer biotherapy & radiopharmaceuticals·2026
Same author

Molecular Breast Imaging of HER2-Positive Breast Cancer in the Era of PHERGain Trial: The past, the Present, and the Prospects.

Cancer biotherapy & radiopharmaceuticals·2024
Same author

Immunotherapy for Cancer: Something Old, Something New.

Cancer biotherapy & radiopharmaceuticals·2023
Same author

Introduction.

Cancer biotherapy & radiopharmaceuticals·2021
Same author

Agent Optimization: Absorption, Distribution, Metabolism, Excretion, Dose, and Decay.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2020
Same author

Reply to the 'Comment on "Investigation of Zr(iv) and <sup>89</sup>Zr(iv) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging"' by A. Bianchi and M. Savastano, Chem. Commun., 2020, 56, D0CC01189D.

Chemical communications (Cambridge, England)·2020
Same journal

Heterometallic ludwigite M<sub>2.5</sub>T<sub>0.5</sub>(O<sub>2</sub>BO<sub>3</sub>) and (M<sub>2</sub>T)(O<sub>2</sub>BO<sub>3</sub>) (M = Co, Ni, Cu; T = Ti, Sn, Fe) compounds as electrocatalysts.

Dalton transactions (Cambridge, England : 2003)·2026
Same journal

Copper(II) complexes for electrocatalytic dioxygen reduction: controlling selectivity <i>via</i> a proton relay mode.

Dalton transactions (Cambridge, England : 2003)·2026
Same journal

Single- and tri-doping strategies with Mn<sup>2+</sup>, Sn<sup>2+</sup>, and Pb<sup>2+</sup> in cadmium-based metal halides for primary-color and tunable white-light emission.

Dalton transactions (Cambridge, England : 2003)·2026
Same journal

Heterobimetallic aluminium/group 4 complexes derived from single-electron processes initiated by an aluminyl anion.

Dalton transactions (Cambridge, England : 2003)·2026
Same journal

Thermally tunable terahertz smart window based on VO<sub>2</sub> phase change material with broadband absorption and ultra-broadband transmission.

Dalton transactions (Cambridge, England : 2003)·2026
Same journal

Cation-templated synthesis of a Fe<sub>4</sub>Co<sub>20</sub> cyanometallate cluster.

Dalton transactions (Cambridge, England : 2003)·2026
See all related articles

Targeted alpha-therapy uses alpha-particle emitting radionuclides delivered by monoclonal antibodies for cancer treatment. This approach shows promise for eliminating residual disease with less collateral damage than beta-emitters.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Immunotherapy

Background:

  • Monoclonal antibodies are utilized for targeted delivery of therapeutic radionuclides to tumor cells.
  • Radioimmunotherapy (RIT) selection of radionuclide and antibody is critical due to differences between alpha- and beta-particle emission.
  • Alpha-particles offer high linear energy transfer and short path lengths, potentially leading to more specific tumor cell killing with reduced normal tissue damage.

Purpose of the Study:

  • To review the potential of targeted alpha-therapy (TAT) in cancer treatment.
  • To highlight the advantages of alpha-emitters over beta-emitters for RIT.
  • To discuss challenges and future research directions for TAT.

Main Methods:

  • Review of in vitro and in vivo studies on RIT using alpha-emitters.

Related Experiment Videos

  • Analysis of clinical trial data for targeted alpha-therapy.
  • Discussion of advancements in isotope production, radiolabeling, and targeting strategies.

    • Main Results:

    • RIT with alpha-emitters like (213)Bi, (211)At, and (225)Ac has shown significant activity in preclinical models.
    • Limited clinical trials indicate safety, feasibility, and therapeutic activity of TAT.
    • Targeted alpha-therapy is a promising strategy for eliminating minimal residual or micrometastatic disease.

    Conclusions:

    • Targeted alpha-therapy demonstrates potential for effective cancer treatment, particularly for minimal residual disease.
    • Further research is needed in isotope development, delivery systems, and clinical integration.
    • Randomized trials are essential to establish the clinical utility of TAT in standard cancer care.